JASCAYD nerandomilast
Drug Class
Selective phosphodiesterase 4B (PDE4B) inhibitor选择性磷酸二酯酶4B（PDE4B）抑制剂
Mechanism
Nerandomilast selectively inhibits phosphodiesterase 4B (PDE4B), leading to antifibrotic and anti-inflammatory effects in lung tissues by increasing cAMP levels.那米司特选择性地抑制磷酸二酯酶4B（PDE4B），通过增加cAMP水平在肺组织中产生抗纤维化和抗炎作用。
Approved Indication
Treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) in adults.用于治疗成人特发性肺纤维化（IPF）及进展性肺纤维化（PPF）。
What This Means For Patients
Jascayd (nerandomilast) is a selective PDE4B inhibitor indicated for adult patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It works by reducing lung inflammation and tissue scarring (fibrosis). It was approved by both the FDA and the NMPA in late 2025.Jascayd（那米司特）是一种选择性PDE4B抑制剂，用于治疗成人特发性肺纤维化（IPF）和进展性肺纤维化（PPF）。它通过减少肺部炎症和组织疤痕（纤维化）来减缓疾病进展。该药于2025年10月获得美国FDA和中国国家药监局批准上市。
Pivotal Clinical Evidence
- FIBRONEER-IPF — Richeldi et al., N Engl J Med 2022 (NCT04419506) — DOI
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.